Cargando…
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714676/ https://www.ncbi.nlm.nih.gov/pubmed/36465634 http://dx.doi.org/10.3389/fendo.2022.1033479 |
_version_ | 1784842279169556480 |
---|---|
author | Du, Haiyang Meng, Xiaoyu Yao, Yu Xu, Jun |
author_facet | Du, Haiyang Meng, Xiaoyu Yao, Yu Xu, Jun |
author_sort | Du, Haiyang |
collection | PubMed |
description | Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing Aβ deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD. |
format | Online Article Text |
id | pubmed-9714676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97146762022-12-02 The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease Du, Haiyang Meng, Xiaoyu Yao, Yu Xu, Jun Front Endocrinol (Lausanne) Endocrinology Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing Aβ deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9714676/ /pubmed/36465634 http://dx.doi.org/10.3389/fendo.2022.1033479 Text en Copyright © 2022 Du, Meng, Yao and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Du, Haiyang Meng, Xiaoyu Yao, Yu Xu, Jun The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease |
title | The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease |
title_full | The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease |
title_fullStr | The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease |
title_full_unstemmed | The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease |
title_short | The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease |
title_sort | mechanism and efficacy of glp-1 receptor agonists in the treatment of alzheimer’s disease |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714676/ https://www.ncbi.nlm.nih.gov/pubmed/36465634 http://dx.doi.org/10.3389/fendo.2022.1033479 |
work_keys_str_mv | AT duhaiyang themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT mengxiaoyu themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT yaoyu themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT xujun themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT duhaiyang mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT mengxiaoyu mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT yaoyu mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease AT xujun mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease |